GlassScriptPhysician profile
Patrick G Meyers
NPI 1245232305
$11,701.39
in general payments reported to CMS, 2019-2025
22 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,308 · 2020: $584 · 2021: $250 · 2022: $1,334 · 2023: $74.92 · 2024: $31.80 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $224.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $8,778.34 | 2019 | |
| Intuitive Surgical, INC. | $1,644.18 | 2020-2025 | |
| Ethicon INC. | $356.82 | 2019-2020 | |
| Veran Medical Technologies, INC. | $288.52 | 2019-2020 | |
| Glaxosmithkline, LLC. | $188.59 | 2019-2025 | Trelegy Ellipta, Nucala |
| Genentech USA, INC. | $57.27 | 2019-2020 | |
| Medtronic, INC. | $54.66 | 2025 | Illumisite |
| Genzyme Corporation | $46.67 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $36.58 | 2019 | |
| Grifols USA, LLC | $36.31 | 2021-2023 | Prolastin-C Liquid |
| Itamar Medical INC | $34.96 | 2021 | |
| Jazz Pharmaceuticals INC. | $34.41 | 2021-2023 | |
| Philips North America LLC | $18.19 | 2023 | |
| Abbvie INC. | $16.91 | 2021 | |
| Pfizer INC. | $16.13 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $15.93 | 2021 | |
| Mylan Specialty L.P. | $15.22 | 2023 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $14.29 | 2020 | |
| Allergan, INC. | $12.79 | 2020 | |
| Baxter Healthcare | $12.54 | 2022 | |
| Circassia INC. | $11.20 | 2019 | |
| Merck Sharp & Dohme LLC | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Meyers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.